The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target
Activation of the epithelial-mesenchymal transition process (EMT) by which alveolar cells in human lung tissue undergo differentiation giving rise to a mesenchymal phenotype (fibroblast/miofibroblasts) has been well recognized as a key element in the origin of idiopathic pulmonary fibrosis (IPF). He...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-05-01
|
Series: | Frontiers in Molecular Biosciences |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fmolb.2018.00043/full |
id |
doaj-3459f444f4874aba81661aae570b56ac |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ana Galán-Cobo Elena Arellano-Orden Rocío Sánchez Silva José Luis López-Campos José Luis López-Campos César Gutiérrez Rivera Lourdes Gómez Izquierdo Nela Suárez-Luna María Molina-Molina María Molina-Molina José A. Rodríguez Portal Miriam Echevarría |
spellingShingle |
Ana Galán-Cobo Elena Arellano-Orden Rocío Sánchez Silva José Luis López-Campos José Luis López-Campos César Gutiérrez Rivera Lourdes Gómez Izquierdo Nela Suárez-Luna María Molina-Molina María Molina-Molina José A. Rodríguez Portal Miriam Echevarría The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target Frontiers in Molecular Biosciences interstitial lung disease (ILD) fibrosis sarcoidosis aquaporins (AQPs) inflamation type II pneumocytes |
author_facet |
Ana Galán-Cobo Elena Arellano-Orden Rocío Sánchez Silva José Luis López-Campos José Luis López-Campos César Gutiérrez Rivera Lourdes Gómez Izquierdo Nela Suárez-Luna María Molina-Molina María Molina-Molina José A. Rodríguez Portal Miriam Echevarría |
author_sort |
Ana Galán-Cobo |
title |
The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target |
title_short |
The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target |
title_full |
The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target |
title_fullStr |
The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target |
title_full_unstemmed |
The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target |
title_sort |
expression of aqp1 is modified in lung of patients with idiopathic pulmonary fibrosis: addressing a possible new target |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Molecular Biosciences |
issn |
2296-889X |
publishDate |
2018-05-01 |
description |
Activation of the epithelial-mesenchymal transition process (EMT) by which alveolar cells in human lung tissue undergo differentiation giving rise to a mesenchymal phenotype (fibroblast/miofibroblasts) has been well recognized as a key element in the origin of idiopathic pulmonary fibrosis (IPF). Here we analyzed expression of AQP1 in lung biopsies of patients diagnosed with IPF, and compared it to biopsies derived from patients with diverse lung pneumonies, such as hypersensitivity pneumonitis, sarcoidosis or normal lungs. Immunostaining for AQP1 showed a clear increment of AQP1 localized in the alveolar epithelium in biopsies from IPF patients alone. Moreover, to examine the possible participation of AQP1 in the pathophysiology of IPF, we evaluated its role in the pro-fibrotic transformation induced by transforming growth factor (TGF-β) in vitro. Human alveolar epithelial cells (A549), and fibroblasts derived from an IPF patient (LL29), or fibroblasts from healthy normal lung tissue (MRC-5), were treated with TGF-β, and levels of expression of AQP1, as well as those of E-cadherin, vimentin, α-SMA and collagen were analyzed by RT-qPCR, western blot and immunohistochemistry. An increase of AQP1 mRNA and protein after TGF-β treatment (4–72h) was observed either in A549 or IPF fibroblast-LL29 but not in MRC-5 fibroblasts. A gradual reduction of E-cadherin, and increased expression of vimentin, with no changes in α-SMA levels were observed in A549. Whereas in LL29 and MRC-5, TGF-β1 elicited a large production of collagen and α-SMA that was significantly greater in IPF fibroblast-LL29. Changes observed are consistent with activation of EMT by TGF-β, but whether modifications in AQP1 expression are responsible or independent events occurring at the same time is still unknown. Our results suggest that AQP1 plays a role in the pro-fibrotic TGF-β action and contributes to the etiology and pathophysiology of IPF. Understanding AQP1's role will help us comprehend the fate of this disease. |
topic |
interstitial lung disease (ILD) fibrosis sarcoidosis aquaporins (AQPs) inflamation type II pneumocytes |
url |
http://journal.frontiersin.org/article/10.3389/fmolb.2018.00043/full |
work_keys_str_mv |
AT anagalancobo theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT elenaarellanoorden theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT rociosanchezsilva theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT joseluislopezcampos theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT joseluislopezcampos theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT cesargutierrezrivera theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT lourdesgomezizquierdo theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT nelasuarezluna theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT mariamolinamolina theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT mariamolinamolina theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT josearodriguezportal theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT miriamechevarria theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT anagalancobo expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT elenaarellanoorden expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT rociosanchezsilva expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT joseluislopezcampos expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT joseluislopezcampos expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT cesargutierrezrivera expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT lourdesgomezizquierdo expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT nelasuarezluna expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT mariamolinamolina expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT mariamolinamolina expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT josearodriguezportal expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget AT miriamechevarria expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget |
_version_ |
1724864079744466944 |
spelling |
doaj-3459f444f4874aba81661aae570b56ac2020-11-25T02:21:59ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2018-05-01510.3389/fmolb.2018.00043352851The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New TargetAna Galán-Cobo0Elena Arellano-Orden1Rocío Sánchez Silva2José Luis López-Campos3José Luis López-Campos4César Gutiérrez Rivera5Lourdes Gómez Izquierdo6Nela Suárez-Luna7María Molina-Molina8María Molina-Molina9José A. Rodríguez Portal10Miriam Echevarría11Departamento de Fisiología Médica y Biofísica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Sevilla, SpainDepartamento de Fisiología Médica y Biofísica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Sevilla, SpainDepartamento de Fisiología Médica y Biofísica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Sevilla, SpainUnidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocio, Sevilla, SpainCentro de Investigación Biomédica en Red sobre Enfermedades Respiratorias (CIBERES), Madrid, SpainUnidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocio, Sevilla, SpainServicio Anatomía Patológica, HU Virgen del Rocío Sevilla, Seville, SpainDepartamento de Fisiología Médica y Biofísica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Sevilla, SpainCentro de Investigación Biomédica en Red sobre Enfermedades Respiratorias (CIBERES), Madrid, SpainLaboratorio de Neumologia Experimental, Servicio de Neumologia, Institut d'Investigació Biomédica de Bellvitge, Hospital Universitario de Bellvitge, Barcelona, SpainUnidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocio, Sevilla, SpainDepartamento de Fisiología Médica y Biofísica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Sevilla, SpainActivation of the epithelial-mesenchymal transition process (EMT) by which alveolar cells in human lung tissue undergo differentiation giving rise to a mesenchymal phenotype (fibroblast/miofibroblasts) has been well recognized as a key element in the origin of idiopathic pulmonary fibrosis (IPF). Here we analyzed expression of AQP1 in lung biopsies of patients diagnosed with IPF, and compared it to biopsies derived from patients with diverse lung pneumonies, such as hypersensitivity pneumonitis, sarcoidosis or normal lungs. Immunostaining for AQP1 showed a clear increment of AQP1 localized in the alveolar epithelium in biopsies from IPF patients alone. Moreover, to examine the possible participation of AQP1 in the pathophysiology of IPF, we evaluated its role in the pro-fibrotic transformation induced by transforming growth factor (TGF-β) in vitro. Human alveolar epithelial cells (A549), and fibroblasts derived from an IPF patient (LL29), or fibroblasts from healthy normal lung tissue (MRC-5), were treated with TGF-β, and levels of expression of AQP1, as well as those of E-cadherin, vimentin, α-SMA and collagen were analyzed by RT-qPCR, western blot and immunohistochemistry. An increase of AQP1 mRNA and protein after TGF-β treatment (4–72h) was observed either in A549 or IPF fibroblast-LL29 but not in MRC-5 fibroblasts. A gradual reduction of E-cadherin, and increased expression of vimentin, with no changes in α-SMA levels were observed in A549. Whereas in LL29 and MRC-5, TGF-β1 elicited a large production of collagen and α-SMA that was significantly greater in IPF fibroblast-LL29. Changes observed are consistent with activation of EMT by TGF-β, but whether modifications in AQP1 expression are responsible or independent events occurring at the same time is still unknown. Our results suggest that AQP1 plays a role in the pro-fibrotic TGF-β action and contributes to the etiology and pathophysiology of IPF. Understanding AQP1's role will help us comprehend the fate of this disease.http://journal.frontiersin.org/article/10.3389/fmolb.2018.00043/fullinterstitial lung disease (ILD)fibrosissarcoidosisaquaporins (AQPs)inflamationtype II pneumocytes |